UB Paderborn / Katalog / Suche / in CDI

1 – 8 von 8

Sortiert nach

Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer

Annals of oncology, 2020-12, Vol.31 (12), p.1725-1733

2020

Volltextzugriff (PDF)

IA03 Therapeutic Approaches in KRAS-Driven Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2020-02, Vol.15 (2), p.S2-S2

McCoach, C.E.

2020

Volltextzugriff (PDF)

Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy

Annals of oncology, 2017-11, Vol.28 (11), p.2707-2714

2017

Volltextzugriff (PDF)

MO01.01 Durvalumab for Patients with Stage III EGFR-Mutated Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy

Journal of thoracic oncology, 2021-01, Vol.16 (1), p.S15-S15

2021

Volltextzugriff (PDF)

Corrections to “Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy”

Annals of oncology, 2019-03, Vol.30 (3), p.492-492

2019

Volltextzugriff (PDF)

LBA61 First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions

Annals of oncology, 2020-09, Vol.31, p.S1189-S1189

2020

Volltextzugriff (PDF)

Targeting Residual Disease in Oncogene-Driven NSCLC

Journal of thoracic oncology, 2017-08, Vol.12 (8), p.S1546-S1546

2017

Volltextzugriff (PDF)

Osimertinib, a third-generation tyrosine kinase inhibitor targeting non-small cell lung cancer with EGFR T790M mutations

Drugs of today (Barcelona, Spain : 1998), 2016-10, Vol.52 (10), p.561-568

2016

Volltextzugriff (PDF)

1 – 8 von 8

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(7)
Mit Volltextzugriff
(8)

Publikationsform

Artikel
(8)

Sprache

Englisch
(8)
Japanisch
(1)

Erscheinungsjahr

n.n

Kollektion

Zeitschrift / Serie

Menü

Weitere Dienste

Einstellungen

Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer

IA03 Therapeutic Approaches in KRAS-Driven Non-Small Cell Lung Cancer

Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy

MO01.01 Durvalumab for Patients with Stage III EGFR-Mutated Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy

Corrections to “Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy”

LBA61 First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions

Targeting Residual Disease in Oncogene-Driven NSCLC

Osimertinib, a third-generation tyrosine kinase inhibitor targeting non-small cell lung cancer with EGFR T790M mutations

Suchergebnisse filtern